What is the 13F Pro Quality Score for ARTV?

13F Pro ranks Artiva Biotherapeutics, Inc. (ARTV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ARTV's current score at https://13fpro.ai/company/ARTV (free sign-up required for the full ranking).

Which hedge funds own the most ARTV stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ARTV include RA CAPITAL MANAGEMENT, L.P., VIKING GLOBAL INVESTORS, Blackstone. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ARTV as soon as new 13F filings post.

Where does 13F Pro source ARTV data?

All Artiva Biotherapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Artiva Biotherapeutics, Inc. files with the SEC under CIK 1817241. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ARTV in?

Artiva Biotherapeutics, Inc. (ARTV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ARTV research updated on 13F Pro?

ARTV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Artiva Biotherapeutics, Inc.(ARTV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1817241 ARTV stock profile & AI dashboard →

13F Pro Quality Score

9.7/100

Rank #2,711 of 2,748 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

0.3/100

Balance Sheet

5.4/100

Earnings Quality

10.3/100

Free Cash Flow

0.2/100

Institutional Flow

10.7/100

Revenue Scale

0.3/100

Dilution Risk

0.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ARTV Scores 10/100

exact factor attribution · 2026-03-09

ARTV's composite is held back by free cash flow and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

-1.0 pts

30th pct

Institutional flow

-2.0 pts

11th pct

Shareholder dilution

-2.5 pts

0th pct

Earnings quality

-4.0 pts

10th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.5 pts

5th pct

Profitability

-7.5 pts

0th pct

Scale

-7.5 pts

0th pct

Free cash flow

-7.5 pts

0th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ARTV Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Artiva Biotherapeutics, Inc. (ARTV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARTV at 9.7/100 on a 32-signal composite quality model, placing it at rank #2,711 of 2,748 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.2) and profitability (0.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Artiva Biotherapeutics, Inc. reports net income of $-25.0M, free cash flow of $-20.8M. Top institutional holders of ARTV by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., VIKING GLOBAL INVESTORS, Blackstone, based on the most recent SEC filings. ARTV trades on the Nasdaq exchange and files with the SEC under CIK 1817241. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARTV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Artiva Biotherapeutics, Inc. directly from SEC EDGAR. Artiva Biotherapeutics, Inc.'s 13F Pro composite quality score has ranged between 10 and 42 since 2025, currently 9.7 — a declining long-term trajectory across 17 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-25.0M

Free Cash Flow

Q2 2026

$-20.8M

ROIC

Q2 2026

-30.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-100.0% YoY

$0.00FY 2025

FY22 —FY23 $33.5MFY24 $251.0KFY25 $0.00

Net Income

-28.3% YoY

$-83.9MFY 2025

FY22 —FY23 $-28.7MFY24 $-65.4MFY25 $-83.9M

Operating Income

-33.5% YoY

$-89.8MFY 2025

FY22 —FY23 $-30.7MFY24 $-67.3MFY25 $-89.8M

EPS (Diluted)

+41.0% YoY

$-3.43FY 2025

FY22 —FY23 $-35.78FY24 $-5.81FY25 $-3.43

Total Assets

-37.5% YoY

$130.9MFY 2025

FY22 —FY23 $105.1MFY24 $209.6MFY25 $130.9M

Op. Cash Flow

-39.5% YoY

$-76.8MFY 2025

FY22 —FY23 $-47.4MFY24 $-55.0MFY25 $-76.8M

Free Cash Flow

-42.5% YoY

$-79.3MFY 2025

FY22 —FY23 $-50.7MFY24 $-55.7MFY25 $-79.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Revenue	$0.00 -100.0%	$251.0K -99.3%	$33.5M	—
Net Income	$-83.9M -28.3%	$-65.4M -127.6%	$-28.7M	—
Operating Income	$-89.8M -33.5%	$-67.3M -119.4%	$-30.7M	—
EPS (Diluted)	$-3.43 +41.0%	$-5.81 +83.8%	$-35.78	—
Total Assets	$130.9M -37.5%	$209.6M +99.4%	$105.1M	—
Operating Cash Flow	$-76.8M -39.5%	$-55.0M -16.0%	$-47.4M	—
Free Cash Flow	$-79.3M -42.5%	$-55.7M -9.8%	$-50.7M	—

Get alerted when ARTV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Artiva Biotherapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ARTV

RA CAPITAL MANAGEMENT, L.P.
$174.2M17,955,642 sh
VIKING GLOBAL INVESTORS LP
$25.3M2,604,166 sh
Blackstone Inc.
$23.3M2,403,437 sh
5AM Venture Management, LLC
$22.8M2,353,304 sh
VR Adviser, LLC
$19.8M2,043,596 sh
FRANKLIN RESOURCES INC
$19.4M1,997,223 sh
Caligan Partners LP
$16.8M1,736,111 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.5M981,815 sh
Samsara BioCapital, LLC
$9.3M954,861 sh
Blue Owl Capital Holdings LP
$8.5M874,542 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$174.2M	17,955,642
VIKING GLOBAL INVESTORS LP	$25.3M	2,604,166
Blackstone Inc.	$23.3M	2,403,437
5AM Venture Management, LLC	$22.8M	2,353,304
VR Adviser, LLC	$19.8M	2,043,596
FRANKLIN RESOURCES INC	$19.4M	1,997,223
Caligan Partners LP	$16.8M	1,736,111
VANGUARD CAPITAL MANAGEMENT LLC	$9.5M	981,815
Samsara BioCapital, LLC	$9.3M	954,861
Blue Owl Capital Holdings LP	$8.5M	874,542

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ARTV on your watchlist

Track score changes the day Artiva Biotherapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ARTV a good stock to buy?

13F Pro's AI-powered analysis of Artiva Biotherapeutics, Inc. (ARTV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARTV are available on the ARTV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ARTV is classified as a small company.

Which hedge funds own ARTV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARTV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Artiva Biotherapeutics, Inc.'s investment landscape.